СОВРЕМЕННЫЕ ПОДХОДЫ К МЕДИКАМЕНТОЗНОМУ ЛЕЧЕНИЮ ОЖИРЕНИЯ
Ключевые слова:
ожирение, медикаментозное лечение ожирения, лираглутид, семаглутид, орлистат, сибутраминАннотация
Ожирение, являясь хроническим и рецидивирующим заболеванием нарушает не только обмен веществ, но также является фактором риска сердечно-сосудистых заболеваний. Учитывая, что поведенческая терапия играет немаловажную роль в лечении ожирения, трудно достичь идеального веса и поддержать процесс долгосрочного снижения на фоне нее. Поэтому руководство по борьбе с ожирением настоятельно рекомендует начало медикаментозной терапии у пациентов с ИМТ ≥30 кг/м 2 и ИМТ ≥27 кг/м 2 с сопутствующими заболеваниями, связанными с массой тела, такими как СД2. Существует достаточно доказательств, подтверждающих, что фармакотерапия в сочетании с поведенческими мероприятиями может привести к значительной потере веса и снижению риска развития сердечно-сосудистых осложнений.
Одна из стратегий долгосрочного контроля ожирения заключается в том, что препараты по снижению веса должны быть подобраны индивидуально для каждого пациента, в зависимости от их сопутствующих заболеваний и предпочтений.
Библиографические ссылки
Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А. и др. Ожирение. Клинические рекомендации. М.; 2020. 43 с. [DedovI.I., MokryshevaN.G., MelnichenkoG.A. etal. Obesity. Clinical recommendations. М.; 2020. 43 p. (in Russian)]
Трошина Е.А., Ершова Е.В. Фармакотерапия ожирения — что нового. Проблемы эндокринологии. 2018; 64(4): 270–6. [TroshinaE.A., ErshovaE.V. Pharmacotherapyofobesity: what’snew? Problems of Endocrinology. 2018; 64(4): 270–6. (in Russian)]. DOI: 10.14341/probl8759
Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose escalation study. J Clin Endocrinol Metab. 2007;92(8):2977–83.
Aronne LJ, Halseth AE, Burns CM, Miller S, Shen LZ. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity (Silver Spring). 2010;18(9):1739–46.
Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled- release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20:330–42.
Brandt S, Kleinert M, Tschöp M, et al. Are peptide conjugates the golden therapy against obesity? J Endocrinol. 2018;238(2):109-19. doi:10.1530/JOE-18-0264
Bhat SP, Sharma A. Current drug targets in obesity pharmacotherapy - a review. Curr Drug Targets. 2017;18(8):983–93.
Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes ObesMetab. 2017;19(9):1242–51.
Cercato C, Fonseca FA. Cardiovascular risk and obesity. DiabetolMetabSyndr. 2019;11:74.
Cataldi M, Muscogiuri G, Savastano S, Barrea L, Guida B, Taglialatela M, Colao A. Gender- related issues in the pharmacology of new anti-obesity drugs. Obes Rev. 2019. PMID: 30589980 Review.
Coulter AA, Rebello CJ, Greenway FL. Centrally acting agents for obesity: past, present, and future. Drugs. 2018;78(11):1113– 32.
Frias J, Bastyr E, Vignati L, et al. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2. Diabetes Cell Metab. 2017;26(2):343-52. doi:10.1016/j.cmet.2017.07.011
Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297– 308.
Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022–9.
Heymsfield SB, Wadden TZ. Mechanisms, phathophysiology and management of obesity. N Engl J Med. 2017;376(3):254–66.
James W.P., Astrup A., Finer N. et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000; 356(9248): 2119–25. DOI: 10.1016/s0140-6736(00)03491-7
James W.P., Caterson I.D., Coutinho W. et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med. 2010; 363(10): 905–17. DOI: 10.1056/NEJMOA1003114
Jimenez V, Jambrina C, Casana E, et al. FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Mol Med. 2018;10(8):e8791. doi:10.15252/emmm.201708791
Jeon WS, Park CY. Antiobesity pharmacotherapy for patients with type 2 diabetes: focus on long-term management. Endocrinol Metab (Seoul). 2014;29:410–7.
Monami M, Nreu B, Scatena A, Cresci B, Andreozzi F, Sesti G, et al. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diabetes ObesMetab. 2017;19(9): 1233–41.
Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Pp. 252. (World Health Organization, Geneva, 2000.) SFr 56.00, ISBN 92-4-120894-5, paperback.
Patel DK, Stanford FC. Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgrad Med. 2018;130(2):173–82. CurrObes Rep (2021) 10:14–30 27
Sánchez-Garrido M, Brandt S, Clemmensen C, et al. GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia. 2017;60(10):1851-61. doi:10.1007/ s00125-017-4354-8.
Seo MH, Lee WY, Kim SS, Kang JH, Kang JH, Kim KK, et al. Committee of Clinical Practice Guidelines, Korean Society for the Study of Obesity (KSSO). 2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea. J ObesMetabSyndr. 2019;28(1):40–5.
Sharretts J, Galescu O, Gomatam S, Andraca-Carrera E, Hampp C, Yanoff L. NEJM cancer risk associated with lorcaserin — the FDA’s review of the CAMELLIA-TIMI 61 Trial. N Engl J Med. 2020;383(11):1000–2.
Tillner J, Posch M, Wagner F, et al. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo controlled first-inhuman and first-in- patient trials. Diabetes Obes Metab. 2019;21(1):120-8. doi:10.1111/ dom.13494.
Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155– 61.
Usui R, Yabe D, Seino Y. Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity. J Diabetes Investig. 2019;10(4):902-5. doi:10.1111/jdi.13005
Velazquez A, Apovian CM. Updates on obesity pharmacotherapy. Ann N Y Acad Sci 2018;1411(1):106–119.
Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes. 2013;37(11):1443–51.
